Brain Cancer | Specialty

Dr. Upadhyaya on Radiation Therapy for Young Children with Ependymoma

July 6th 2018

Santhosh Upadhyaya, MD, neuro-oncologist, St. Jude Children’s Research Hospital, discusses radiation therapy for young children under the age of 3 who have ependymoma.

Oncolytic Poliovirus Shows Sustained Survival Rates for Recurrent GBM

June 26th 2018

Treatment with the recombinant oncolytic poliovirus PVSRIPO elicited sustained a 2- and 3-year overall survival (OS) rate of 21% (95% CI, 11%-33%) for patients with recurrent grade IV malignant glioblastoma.

Carboxyamidotriazole Orotate Shows Promising Activity in Brain Cancers

April 28th 2018

Carboxyamidotriazole orotate in combination with temozolomide, with or without radiotherapy, produced positive safety and efficacy results in a phase Ib study of patients with glioblastoma or anaplastic gliomas.

NCCN Recommends TTFields With Temozolomide for Newly Diagnosed GBM

March 21st 2018

The NCCN has added the combination of TTFields (Optune) and temozolomide (Temodar) to its guidelines for Category 1 treatment of newly diagnosed glioblastoma following maximal safe resection and completion of radiation therapy.

Research Strategies to Improve Outcomes in GBM

March 5th 2018

GBM Emerging Strategies in Immunotherapy

March 5th 2018

GBM Rationale for Combining PD1 Inhibitor DNA Vaccine

March 5th 2018

PD1 Inhibitor DNA Vaccine Combination Trial in GBM

March 5th 2018

DNA Vaccine Creating Immunogenicity in GBM

March 5th 2018

Efficacy of Checkpoint Inhibition in Glioblastoma

March 5th 2018

Challenges With Immunotherapy in Glioblastoma

March 5th 2018

Novel Combo Explored for Rare Brain Tumor

March 5th 2018

Investigators are seeking to determine whether the combination of eflornithine with lomustine can improve survival for patients with recurrent anaplastic astrocytoma.

DNX-2401 Demonstrates "Dramatic" Survival Benefit in Glioma

February 15th 2018

Treatment with the investigational agent DNX-2401 resulted in 20% of a cohort of patients with recurrent malignant glioma surviving more than 3 years from the time of treatment.

Tumor-Treating Fields Extend Survival in Glioblastoma

January 19th 2018

Adding tumor-treating fields to temozolomide resulted in improved progression-free survival and overall survival for patients with glioblastoma.

Oncolytic Virus Therapy Passes Early Efficacy Tests in Glioma Subtypes

January 7th 2018

A2-step oncolytic virus has demonstrated promising signals against aggressive forms of brain cancers, including recurrent glioblastoma multiforme and anaplastic astrocytoma, in early clinical studies.

FDA Grants Bevacizumab Full Approval for Glioblastoma

December 6th 2017

The FDA has granted bevacizumab a full approval for the treatment of adult patients with glioblastoma that progressed following prior therapy.

Immunotherapy Combinations Offer Hope in Glioblastoma

October 4th 2017

Immunotherapy has shown promise for treatment of glioblastoma multiforme (GBM), the most common primary brain tumor in adults with historically poor prognosis, but experts agree that combination regimens have the greatest potential to achieve durable response.

FDA Approves First Biosimilar for Cancer Treatment

September 14th 2017

The FDA approved the first biosimilar for the treatment of cancer. ABP-215 (bevacizumab-awwb; Mvasi), a biosimilar for bevacizumab (Avastin), is indicated for the treatment of colorectal, lung, brain, kidney, and cervical cancers in adult patients.

Glioblastoma Platform Trial Investigating Multiple Drugs in Parallel

September 6th 2017

In an ongoing phase II trial, researchers are investigating several targeted agents for use in the treatment of patients with glioblastoma (GBM).

ODAC Unanimously Supports Bevacizumab Biosimilar ABP-215

July 13th 2017

The FDA’s Oncologic Drugs Advisory Committee voted 17-0 to recommend approval for ABP-215, a biosimilar for bevacizumab (Avastin) to treat a range of solid tumors.